Lupus Nephritis
SGLT2 inhibitors have ‘potential role’ in reducing cardiac, renal risks in lupus
SAN DIEGO — Patients with lupus who received sodium-glucose cotransporter-2 inhibitors demonstrated reduced risks for major adverse cardiovascular events and kidney disease, a speaker said at ACR Convergence 2023.
Obinutuzumab improves odds of complete renal response, cuts flare risk in lupus nephritis
SAN DIEGO — Obinutuzumab use increases the chances of achieving complete renal response and lowers the risk for kidney-related events and time to flare in lupus nephritis, according to data presented at ACR Convergence 2023.
FDA grants breakthrough therapy designation to felzartamab
The FDA has granted breakthrough therapy designation for felzartamab, an investigational antibody to treat primary membranous nephropathy.
Voclosporin exhibits positive long-term safety, efficacy data over 3 years
Long-term voclosporin is safe and efficacious for the treatment of lupus nephritis over 3 years, according to data published in Arthritis & Rheumatology.
Lupus Research Alliance grants $3 million award to study pediatric lupus nephritis
‘A very exciting time’: Voclosporin, cell therapies represent future of lupus treatment
SAN DIEGO —The recent voclosporin approval and continued research into cell therapies make this a “very exciting time” for lupus nephritis therapy, according to a speaker 2023 Congress of Clinical Rheumatology West.
FDA clears IND application for ‘allogenic, off-the-shelf’ cell therapy for lupus nephritis
The FDA has cleared an investigational new drug application for AlloNK in combination with rituximab to treat systemic lupus erythematosus in patients with active lupus nephritis, according to a press release from Artiva Biotherapeutics.
FDA grants fast-track designation to second CAR T-cell therapy for lupus nephritis
The FDA has granted fast-track designation to Kyverna’s KYV-101, a novel anti-CD19 chimeric antigen receptor T-cell therapy for patients with refractory lupus nephritis, according to a company press release.
Lupus Research Alliance announces largest prospective study of SLE, new patient registry
The Lupus Research Alliance, alongside its research affiliate Lupus Therapeutics, have announced the launch of what would be the largest prospective observational study into lupus, as well as a new patient registry and data resource.
Despite retinopathy concerns, hydroxychloroquine still proven to boost survival in lupus
DESTIN, Fla. — Hydroxychloroquine remains one of the most important drugs in lupus management and should be used as background therapy in nearly all cases, according to a speaker at the Congress of Clinical Rheumatology East annual meeting.